Counterpoint Mutual Funds LLC Invests $565,000 in AxoGen, Inc. (NASDAQ:AXGN)

Counterpoint Mutual Funds LLC purchased a new stake in AxoGen, Inc. (NASDAQ:AXGN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 34,275 shares of the medical equipment provider's stock, valued at approximately $565,000. Counterpoint Mutual Funds LLC owned about 0.08% of AxoGen as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Quest Partners LLC raised its stake in AxoGen by 23,066.7% during the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 2,076 shares during the last quarter. R Squared Ltd bought a new position in shares of AxoGen during the 4th quarter worth about $30,000. US Bancorp DE acquired a new position in shares of AxoGen during the fourth quarter valued at about $30,000. Oppenheimer & Co. Inc. bought a new stake in shares of AxoGen in the third quarter valued at about $156,000. Finally, Quantbot Technologies LP acquired a new stake in AxoGen during the third quarter worth about $165,000. 80.29% of the stock is currently owned by institutional investors.

AxoGen Price Performance

Shares of NASDAQ AXGN traded down $0.32 during midday trading on Friday, reaching $17.72. 460,457 shares of the company traded hands, compared to its average volume of 398,442. AxoGen, Inc. has a 12 month low of $5.55 and a 12 month high of $21.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The stock's 50-day simple moving average is $18.25 and its 200-day simple moving average is $15.60. The firm has a market cap of $785.78 million, a PE ratio of -55.38 and a beta of 1.02.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $24.00 price objective on shares of AxoGen in a research report on Wednesday, March 5th. Canaccord Genuity Group raised their target price on AxoGen from $22.00 to $26.00 and gave the stock a "buy" rating in a research report on Wednesday, February 26th. Finally, Lake Street Capital started coverage on shares of AxoGen in a report on Monday. They issued a "buy" rating and a $30.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, AxoGen has an average rating of "Buy" and an average price target of $22.60.

Insider Transactions at AxoGen

In other news, insider Erick Wayne Devinney sold 15,111 shares of the stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total transaction of $264,442.50. Following the sale, the insider now owns 217,762 shares in the company, valued at approximately $3,810,835. This represents a 6.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Amy Mcbride Wendell sold 5,000 shares of AxoGen stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $20.02, for a total value of $100,100.00. Following the completion of the transaction, the director now directly owns 97,899 shares of the company's stock, valued at $1,959,937.98. This represents a 4.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.00% of the company's stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.